- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ALI adds multimodality version of UltraPACS
ALI adds multimodality version of UltraPACSALI Technologies continues to grow beyond its traditional role as an ultrasound miniPACS supplier. The Richmond, BC-based firm has introduced ALI UltraPACS NT Version 4, an image management system that
ALI adds multimodality version of UltraPACS
ALI Technologies continues to grow beyond its traditional role as an ultrasound miniPACS supplier. The Richmond, BC-based firm has introduced ALI UltraPACS NT Version 4, an image management system that can support major medical image modalities. ALI expects to begin shipping the new offering this year.
ALI plans to install its first beta site at Tower Radiology in Los Angeles, which will incorporate the UltraPACS unit into its CR, CT, MRI, fluoroscopy, nuclear medicine, and ultrasound clinical operations. ALI's UltraPACS will also connect two of Tower Radiology's imaging centers, creating a single imaging network with a common clinical database.
Since introducing its UltraPACS system, ALI has installed units at approximately 200 sites worldwide. In other ALI news, the company has received a 1998 Canada Export Award. The awards recognize Canadian firms that have successfully exported their products and services.
- Search again
- Homepage
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
